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Introduction 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (1) on 25 April 2017, the EMCDDA and Europol 
launched the Joint Report procedure for N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-
yl]propanamide (4-fluoroisobutyrylfentanyl) on the basis of data reported by the Member States to the 
European Union Early Warning System in accordance with Article 4 of the Council Decision. The 
information collection process for the Joint Report was completed in June 2017. The report was submitted 
to the Institutions of the European Union in July 2017 (EMCDDA, 2017a). In accordance with Article 6 of 
the Council Decision, on 14 September 2017, the Council of the European Union requested that a risk 
assessment on 4-fluoroisobutyrylfentanyl should be carried out by the extended Scientific Committee of 
the EMCDDA. 
In order to prepare for a risk assessment, and, to facilitate the risk assessment process, the EMCDDA is 
responsible for the collection and analysis of data on the substance to be assessed as well as drafting a 
technical report. This technical report has been prepared for the risk assessment of 4-
fluoroisobutyrylfentanyl that will be held at the EMCDDA premises in Lisbon on Wednesday 8 November 
2017. 
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.17.SAT.0084.1.0 
and CT.17.SAT.0110.1.0). 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey, and Norway to the EMCDDA and Europol in 
accordance with the Council Decision (EMCDDA, 2017a); and,  
 data collected through systematic searches of open source information, including the scientific 
and medical literature, patents, official reports, grey literature, Internet drug discussion forums 
and related websites, and online vendors selling 4-fluoroisobutyrylfentanyl. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in October 2017. The retrieved publications were then reviewed for additional relevant 
references (snowballing technique). 
Chemical structure-based searches were done in SciFinder® (American Chemical Society, Chemical 
Abstract Service) and Reaxys® (Elsevier) databases using both the exact structure of 4-
                                                     
(1) OJ L 127, 20.5.2005, p. 32.  
4 
fluoroisobutyrylfentanyl and a similarity search. Structural and text-based searches in the SureChEMBL 
patent database retrieved only one, though irrelevant, hit (2). 
Textual searches were conducted online in PubMed (National Center for Biotechnology Information), Web 
of  (Thomson Reuters), and in popular English-language drug forums. The search terms used 
were: -  4-fluoro-  -fluoro-  -fluoro-
 para-  4-F-iBF, 4-FiBF, 4-FIBF, FIBF, p-FIBF and p-FiBF. 
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) was 
searched using the CAS registry numbers listed below. The searches returned no hits. 
Cursory, though repeated, inspections of English-language Internet forums covered Bluelight, Drugs-
forum, ecstasydata.org, Erowid, Eve&Rave, Reddit and The Vespiary. 
Additionally, the scientific networks of the authors were contacted to obtain information. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; similarly it 
is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the actual 
composition of the substance/product may differ over time and different geographical areas. In addition, 
the information provided on user websites may not necessarily be representative of other users of 4F-iBF 
and should be regarded as illustrative only. In general, given the difficulties of collecting accurate self-
reported data, it should be interpreted with caution. 
Reported prepared by 
Simon Brandt (3), Simon Elliott (4), Michael Evans-Brown (5), Helgi Valur Danielsson (5), Anabela Almeida 
(5), Rita Jorge (5), Rachel Christie (5), Ana Gallegos (5), and Roumen Sedefov (5). 
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The EMCDDA would like to extend their sincere thanks and appreciation to: the Early Warning System 
(EWS) correspondents of the Reitox national focal points and experts from their national early warning 
system networks; the Europol national units and Europol Project Synergy; and, Dr István Ujváry, iKem 
BT, Budapest, Hungary for reviewing some of the sections of this report. 
  
                                                     
(2) A recent US patent mentions p-  as one of the opioids against which a novel nasal naloxone spray 
formulation can be applied (Keegan et al., 2017). 
(3) School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, United Kingdom. 
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Section A. Physical, chemical, pharmaceutical and pharmacological information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4-fluoroisobutyrylfentanyl) is 
structurally related to fentanyl, which is a fast and short-acting synthetic opioid that has been widely used 
in clinical practice as an adjunct to general anaesthesia during surgery and for postoperative pain 
management. 4-Fluoroisobutyrylfentanyl contains one basic nitrogen atom in the piperidine ring readily 
forming salts with organic or inorganic acids.  
4-Fluoroisobutyrylfentanyl is also structurally related to acetylfentanyl, acryloylfentanyl, and 
furanylfentanyl, which were the subjects of EMCDDA Europol Joint Reports submitted in December 
2015, November 2016 and January 2017, respectively, following reports of deaths in Europe (EMCDDA, 
2016a; EMCDDA, 2017b; EMCDDA, 2017c). In February 2017 and May 2017, risk assessment meetings 
on acryloylfentanyl (EMCDDA, 2017d) and furanylfentanyl (EMCDDA, 2017e) were convened under the 
auspices of the Scientific Committee of the EMCDDA following the request by the Council of the 
European Union. On 25 September 2017, the Council of the European Union decided that 
acryloylfentanyl should be subjected to control measures across the European Union (CEU, 2017). 
4-Fluoroisobutyrylfentanyl differs from fentanyl by the presence of a fluorine atom on the anilido phenyl 
ring and the presence of an isobutyramide group in place of the propanamide group. 4-
Fluoroisobutyrylfentanyl is the positional isomer of 4-fluorobutyrfentanyl (4F-BF) and thus both 
substances are structurally very closely related, which results in the same molecular formula and 
molecular mass. The molecular structure, molecular formula, and molecular mass of 4-
fluoroisobutyrylfentanyl are provided in Figure 1.  
The first reference to 4-fluoroisobutyrylfentanyl in the scientific literature appears to have been in a paper 
published in 1999, wherein the synthesis of the substance and analytical discrimination from fentanyl was 
reported (Ohta, 1999). 
4-fluoroisobutyrylfentanyl 4-fluorobutyrylfentanyl Fentanyl 
C23H29FN2O C23H29FN2O C22H28N2O 
368.50 g/mol 368.50 g/mol 336.48 g/mol 
Figure 1. The molecular structure, molecular formula and molecular mass of 4-fluoroisobutyrylfentanyl (left), 4-
fluorobutyrylfentanyl (middle) and fentanyl (right). 
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Fifteen fentanils are controlled under the United Nations Single Convention on Narcotic Drugs, 1961, as 
amended by the 1972 Protocol: 3-methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
acetylfentanyl, alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, beta-
hydroxyfentanyl, para-fluorofentanyl and thiofentanyl, are controlled under Schedule I and IV; alfentanil, 
butyrfentanyl, fentanyl, remifentanil and sufentanil are controlled under Schedule I. The controls on 
acetylfentanyl and butyrfentanyl entered into force in 2016 and 2017, respectively. 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) name: 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide  
Chemical Abstract name:  
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide 
Other names:  
N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide; 
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide;  
N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidyl]propanamide; 
N-(4-Fluorophenyl)-N-(1-phenethyl-4-piperidinyl)isobutyramide; 
N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide 
Chemical Abstract Service Registry Numbers (CAS RNs) (6) 
244195-32-2. 
PubChem SID:  
Could not be identified (7). 
IUPAC International Chemical Identifier Key (InCHI Key)(8): OZDOSQNUJIXEOR-UHFFFAOYSA-N 
SMILES (9):CC(C)C(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=C(F)C=C3 
                                                     
(6) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical Abstract 
Service Division of the American Chemical Society to a specific, single chemical substance. 
(7) As of 21.10.2017 
(8) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
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Common names:  
4-fluoroisobutyrylfentanyl, 4-fluoro-isobutyrylfentanyl, 4-fluoro-isobutyrfentanyl, para-
fluoroisobutyrylfentanyl, 4-F-iBF, 4-FiBF, 4-FIBF, FIBF, p-FIBF, p-FiBF. 
Street names:  
The street names for 4-fluoroisobutyrylfentanyl may include the common names. 
Identification and analytical profile 
Physical description  
4-Fluoroisobutyrylfentanyl hydrochloride has been described as a neat solid (Cayman Chemical 
Company, 2017) and as a white powder (base) (SWGDRUG, 2016). Due to its similarity to fentanyl, the 
free base could be expected to be sparingly soluble in water; the hydrochloride and citrate salt could be 
expected to have greater aqueous solubility. 4-Fluoroisobutyrylfentanyl is expected to be lipophilic. This 
substance has been seized as a powder, in tablet form, and as a liquid. A more detailed description of 
seizures and collected samples can be found in Section C. 
Chemical stability and typical reactions 
Specific information about 4-fluoroisobutyrylfentanyl could not be identified. For long-term storage it is 
recommended that 4-fluoroisobutyrylfentanyl, supplied as a solid, is stored at -20 °C (Cayman Chemical 
Company, 2017) 
Analytical profile 
As summarized in Table 1, some analytical data have been published.  
It is possible that immunoassays for fentanyl may not distinguish between 4-fluoroisobutyrylfentanyl and 
fentanyl due to the structural similarity between the two substances. Identification of 4-
fluoroisobutyrylfentanyl therefore would require further confirmatory analysis using more suitable 
detection techniques based on, for example, (tandem) mass spectrometry (Helander et al., 2017). 
Similarly, 4-fluoroisobutyrylfentanyl is not expected to give a positive response to tests developed for 
morphine-type opioids. An analytical challenge might arise from the number of potential positional 
isomers that could exist as a result of the presence of the fluorine atom. For example, three fluorophenyl 
and three fluorophenylethyl isomers (2F-, 3F-, 4F-) can exist when just considering the two phenyl rings 
present in the molecule. These six isomers could also apply to the 4-fluorobutyrylfentanyl counterparts, 
thus, potentially giving rise to twelve isomers. Information about the detection of isomers other than 4-
fluoroisobutyrylfentanyl could not be identified. The availability of standard reference material is 
recommended in order to facilitate their differentiation. 
Analytical difficulty arises due to the isobaric nature and very similar fragmentation patters of 4-
fluoroisobutyrylfentanyl and 4-fluorobutyrylfentanyl. Forensic laboratories, being aware of this, often 
                                                                                                                                                                           
(9) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources. 
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report results as 4-fluoroisobutyrylfentanyl/4-  for samples where the isobaric 
substances were not, or could not be, separated. 
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Table 1. Information associated with the detection and chemical analysis of 4-fluoroisobutyrylfentanyl (amongst other 
substances). a 
Techniques b Comment  Reference 
TLC, GC-FID, direct inlet EI-MS, IR  Synthesis and analytical 
characterisation. 
Ohta et al. (1999) 
1H-NMR, GC-MS, FTIR-ATR 
  
Analytical characterisation of 
reference material. 
SWGDRUG (2016) 
GC-MS Analytical characterisation of 
reference material. 
Cayman Chemical Company (2017) 
GC-MS, LC-MS/MS Blood analysis of  cases. DeRienz et al. (2017) 
LC-MS(/MS) Analysis of serum and urine sample 
obtained from an intoxication case in 
September 2016. 
Helander et al. (2017) 
LC-MS/MS Method validation and application to 
analysis of postmortem biological 
sample material. 
Kahl et al. (2017) 
GC-MS Retrospective analysis of GC-MS 
results obtained from blood samples. 
Newmeyer et al. (2017) 
GC-MS, GC-NPD Detection in blood sample. Poston et al. (2017) 
GC-MS, GC-FTIR (condensed 
phase)  
 
Analytical characterisation of 
reference material. 
Slovenian National Forensic 
Laboratory (2017) 
GC-MS Analysis of drug paraphernalia 
(spoon residue) found at the site of 
fatal intoxication.c  
Swanson et al. (2017) 
LC-MS/MS Analysis of postmortem and human 
performance toxicology casework 
Turri et al. (2017) 
LC-MS(/MS) In vitro metabolism using pooled 
human hepatocytes and analysis of 
authentic human urine samples. 
Watanabe et al. (2017) 
GC-MS, LC-MS Analysis of drug paraphernalia 
(spoon residue) and analysis of 
postmortem blood specimen.  
Zaney et al. (2017) 
a As of 21 October 2017. 
b TLC: Thin-layer chromatography; GC: gas chromatography; FID: flame ionization detection; EI: electron ionization; 
MS: mass spectrometry; IR: infrared spectroscopy; NMR: nuclear magnetic resonance spectroscopy; FT: Fourier 
transform; ATR: attenuated total reflectance; LC: liquid chromatography; MS/MS: tandem MS; NPD: nitrogen 
phosphorus detector;  
10 
c Identification based on mass spectral library comparison only. 
 
Methods and chemical precursors used for the manufacture 
No information was reported by the Member States, Turkey, or Norway, about the chemical precursors or 
manufacturing methods used to make the 4-fluoroisobutyrylfentanyl that has been detected within 
Europe.  
Synthesis 
A synthesis procedure for 4-fluoroisobutyrylfentanyl could not be identified in the published literature but it 
seems likely that its synthesis relies on precursors and synthetic methods similar to those used for the 
manufacture of pharmaceutical fentanyl and other fentanyl analogues. Accordingly, methods adapted for 
the multistep synthesis of fentanyl are applicable to 4-fluoroisobutyrylfentanyl whereby the final reaction 
step is expected to apply the acylation of the N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine 
intermediate, a precursor analogous to the N-phenyl-1-(2-phenylethyl)piperidin-4-amine (4-ANPP) 
intermediate involved in the preparation of fentanyl and many of its analogues (Figure 2) (10).  
 
Figure 2. A possible final step of the synthesis of 4-fluoroisobutyrylfentanyl employing the acylation of the N-(4-
fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine intermediate using either isobutyryl chloride or isobutyric anhydride. 
Most of these synthetic procedures are relatively straightforward. Due to the typical high potency of 
fentanils there is a risk of severe poisoning following accidental exposure during their manufacture. 
Extreme care must be taken when carrying out the final synthetic step as well as when purifying and 
handling the substances. Likewise, accidental exposure to the fentanils could pose a risk of poisoning to 
the public, law enforcement, emergency personnel, as well as medical and forensic laboratory personnel. 
In addition to exercising extreme caution when handling materials suspected to contain fentanils, 
personnel should be equipped with appropriate protective equipment. The antidote naloxone should be 
readily available to personnel in sufficient quantities; training in resuscitation, including the administration 
of naloxone, should also be available (IAB, 2017 US CDC, 2013; US CDC, 2016; US DEA, 2017a). Any 
required responses should continue to ensure the delivery of prompt and appropriate care to patients with 
suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
                                                     
(10) Methods not relying on the controlled precursor NPP for the synthesis of 4-fluoroisobutyrylfentanyl are possible. For example, 
alkylation of N-(4-fluorophenyl)-2-methyl-N-(piperidin-4-yl)propanamide by phenethyl chloride would afford the title product. 
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In contrast to the 4-ANPP and its precursor N-phenethyl-4-piperidone (NPP), which were scheduled in 
2017 and are listed in Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988 (CND, 2017; INCB, 2017), the fluorinated analogue of 4-ANPP used for 
the preparation of 4-fluoroisobutyrylfentanyl is not an internationally controlled substance.  
Typical impurities encountered in seized and collected samples 
There are no quantitative data available on the impurities detected in seized and collected samples 
reported to the EMCDDA (Section C). A potentially detectable impurity might be predicted to include the 
N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine intermediate . 
A1.2. Physical/pharmaceutical form  
Data from seizures and collected samples reported to the EMCDDA have noted that 4-
fluoroisobutyrylfentanyl has typically been detected in powders, tablets and liquids (Section C).  
A1.3. Route of administration and dosage  
As with other fentanils, 4-fluoroisobutyrylfentanyl can be administered orally as a powder (including in 
capsules), as tablets, or as a solution (using nasal sprays) or by insufflation of a powder; it can also be 
administered intranasally or sublingually via a spray; inhaled by smoking or vaporizing; and, administered 
by injection (intravenous and intramuscular). There are also instances where 4-fluoroisobutyrylfentanyl is 
advertised for sale in the form of blotters by Internet vendors. Users have also described rectal 
administrations (11). 
Of note is the apparent popularity of selling ready-to-use or homemade nasal sprays containing solutions 
for the administration of fentanils. It is worth noting that some of these products are not always labelled 
and/or sold as another substance, a phenomenon that extends to the use of other fentanils that have 
appeared in Europe in the past few years, including acryloylfentanyl (EMCDDA 2017b; EMCDDA 2017d; 
Ujváry et al., 2017) and furanylfentanyl (EMCDDA, 2017c; EMCDDA, 2017e).  
Dosage 
Limited information is available regarding the dose and the dose regimens of 4-fluoroisobutyrylfentanyl. 
Reports available on user discussion forums included single intravenous administrations up to 5 mg 
followed by nasal spray administrations reportedly amounting to 3 mg over a six-hour period (12). Other 
examples included nasal administrations of 5 mg per day (13);  every 2-3 hours (0.7  up 
to about 0.35 mg  (11); 0.1 0.5 ml intravenous injections of 0.69 mg/mL solutions and 2 mL rectal 
administrations using the same concentration (11); self-prepared nasal spray concentrations of 10 15 
mg/mL have also been mentioned (14). 
                                                     
(11) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF)/page2 (last accessed: 
22.10.2017). 
(12) https://erowid.org/experiences/exp_pdf.php?ID=106906&format=pdf (last accessed 21.10.2017).  
(13) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) (last accessed 21.10.2017). 
(14) https://www.reddit.com/r/opiates/comments/3ved25/anybody_try_furanylfentanyl_fuf_or/ (last accessed 21.10.2017). 
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From this, however, it is not possible to discern the  dosages administered by users. Doses 
appear to differ depending on factors such as the route of administration, the tolerance of the users, the 
use of other drugs, and the desired effects.  
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacologically, 4-fluoroisobutyrylfentanyl is an opioid receptor agonist. 
Pharmacodynamics 
In vitro studies 
The currently available data suggests that 4-fluoroisobutyrylfentanyl binds to the -opioid receptor (MOR) 
with high selectivity over the - and -opioid receptors (KOR and DOR) (Table 2) (15) (US DEA, 2017b).  
Table 2 provides a summary of binding and functional activity data that illustrate that 4-
fluoroisobutyrylfentanyl (EC50 = 115 nM, [35  binding assay, Emax = 91.6%) functioned as a MOR 
agonist (16). In comparison, morphine (EC50 = 17.2 nM, [35  binding assay, Emax = 86.1%) and 
fentanyl (EC50 = 28.8 nM, Emax = 94.0%) were several times more potent than 4-fluoroisobutyrylfentanyl 
and all three test drugs exhibited comparable efficacy (Emax) using this particular in vitro assay. 
4-Fluoroisobutyrylfentanyl showed relatively low affinity toward KOR (Ki = 2,700 nM) with moderate to low 
potency and moderate relative efficacy (EC50 = 1,330 nM, [35  binding assay, Emax = 49.3%). As 
far as DOR was concerned, binding affinity and potency were relatively low, whereas efficacy was 
moderate (Ki = 1,670 nM, EC50 = 2,490 nM, [35  binding assay, Emax = 64%), which suggested a 
MOR selective profile, at least under these in vitro conditions. All test drugs used as positive control were 
shown to be efficacious agonists (Table 2). 
Table 2. Binding and functional activity data for 4-fluoroisobutyrylfentanyl (4F-iBF) generated via the Drug 
Enforcement Administration Veterans Affairs (DEA-VA) Interagency Agreement (modified from US DEA, 2017b). 
MOR 4F-iBF b DAMGO Morphine Fentanyl Naltrexone 
[3H]DAMGO 
binding Ki (nM) 
0.451 ± 0.046 0.277 ± 0.027 0.322 ± 0.048 0.144 ± 0.024 0.082 ± 0.011 
IC50 (nM) 2.16 ± 0.20     
[35  
binding 
4F-iBF b DAMGO Morphine Fentanyl  
Stimulation EC50 
(nM) 
115 ± 33 22.4 ± 7.0 17.2 ± 4.5 28.8 ± 6.9  
Maximal 
stimulation (%)* 
91.6 ± 4.1 96.1 ± 2.2 86.1 ± 5.0 94.0 ± 6.0  
                                                     
(15) Ki represents the equilibrium inhibition constant for the test drug displacing the radioligand. 
(16) EC50 represents the concentration that causes a half-maximal response of the agonist.  
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DOR 4F-iBF b DPDPE-OH Morphine Fentanyl Naltrexone 
[3H]DPDPE 
binding Ki (nM) 
1,670 ± 410 1.93 ± 0.14 79.1 ± 5.1 164 ± 13 8.7 ± 1.0 
IC50 (nM) 2,790 ± 630     
[35  
binding 
4F-iBF b DPDPE-OH Morphine Fentanyl  
Stimulation EC50 
(nM) 
2,490 ± 390 7.4 ± 1.6 750 ± 160 996 ± 99  
Maximal 
stimulation (%)* 
64 ± 15 98.90 ± 0.76 64.0 ± 9.7 42.5 ± 3.6  
KOR 4F-iBF b U-50,488H Morphine Fentanyl Nor-BNI 
[3H]U-69,593 
binding Ki (nM) 
2,700 ± 490 0.143 ± 0.043 34.9 ± 7.0 224 ± 36 0.53 ± 0.17 
IC50 (nM) 4,830 ± 790     
[35  
binding 
4F-iBF b U-50,488H Morphine Fentanyl  
Stimulation EC50 
(nM) 
1,330 ± 290 1.89 ± 0.30 81 ± 10 347 ± 65  
Maximal 
stimulation (%)* 
49.3 ± 5.8 98.1 ± 1.2 87.3 ± 6.7 74.9 ± 9.0  
a In receptor binding experiments, transfected Chinese hamster ovary (CHO) cells expressing human - and -opioid 
receptors and rat -opioid receptors were used. Experimental details for functional activity studies are not reported. 
DOR: delta opioid receptor; KOR: kappa opioid receptor; MOR: mu opioid receptor; DAMGO: Tyr-Ala-Gly-N-Me-Phe-
Gly-ol, DPDPE: Tyr-Pen-Gly-Phe-Pen [disulfide bridge: 2-5]; U-69,593: (+)- -N-methyl-N-[7-(1-pyrrolidinyl)-
1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide; U-50,488H: trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-
pyrrolidinyl)cyclohexyl]benzeneacetamide methanesulfonate salt; Nor-BNI: norbinaltorphimine; U-69,593: (+)-
-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzeneacetamide. SEM: standard error of the 
mean.  
Numbers represent the means ± SEM from at least three independent experiments, each conducted with duplicate 
determinations. Standard compounds are the agonists DPDPE (delta), U-50,488H (kappa) and DAMGO (mu) and the 
antagonists naltrexone (delta and mu) and nor-BNI (kappa). 
* Maximal stimulation by test compound is normalized to the maximal stimulation by DPDPE (delta), U50,488H 
(kappa) or DAMGO (mu) above basal.  
b 4F-iBF: 4-fluoroisobutyrylfentanyl. 
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Animal studies 
It has recently been reported that 4-fluoroisobutyryfentanyl showed analgesic effects in mice 
(subcutaneous administration) in the tail-flick test (55°C). The ED50 value for 4-fluoroisobutyryfentanyl 
was determined at 1.61 mg/kg, compared to 0.122 mg/kg for fentanyl, and 12 mg/kg for morphine. It was 
furthermore reported that naltrexone administration (10 mg/kg, s.c.) affected nociceptive effects as 
demonstrated by a corresponding shift of the dose-response curve to the right (WHO, 2017) (17).  
Pharmacokinetics 
A recent in vitro investigation using human hepatocytes (10 M test drug, up to 5 h incubation time) 
identified 17 metabolites (Figure 3). The identified biotransformations included N-dealkylation (C3), 
hydroxylation (C7, C8, C10, C11, C15, C17) followed by glucuronidation (C5), dihydroxylation (C9), 
dihydrodiol formation (C4), dihydroxylation with methylation (C12, C13) followed by glucuronidation (C6), 
amide hydrolysis (C14), oxidative N-dealkylation, and further reduction of the keto group (C1), 
carboxylation (C2), and carbonylation (C16) (Figure 3) (Watanabe et al., 2017).  
The parent drug was prevalent in both the hepatocyte incubate and authentic human urine samples. Nine 
metabolites were observed in hepatocytes (C3, C8, C10, C12, C14 C17) with the desphenethyl  
metabolite C3 (18) being the major metabolite in the 5 h sample followed by the monohydroxylated 
metabolites C15 and C10. Eleven metabolites were detected in hydrolysed urine (C1, C2, C3, C4, C7, 
C9 C13, C15), which suggested that major metabolites were comparable. The C12 metabolite, a 
potential target for confirming consumption of 4-fluoroisobutyrylfentanyl, was also identified (Watanabe et 
al., 2017). 
 
                                                     
(17) Data provided by the US Drug Enforcement Administration, Food and Drug Administration, National Center for Toxicological 
Research (2017b). Report: 4-Fluoroisobutyryl fentanyl (FIBF), Evaluation of analgesic effects using the warm water tail withdrawal 
assay. 28 June 2017. 
(18) Systematic name: N-(4-Fluorophenyl)-2-methyl-N-(piperidin-4-yl)propanamide. 
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Figure 3. Proposed metabolic pathway of 4-fluoroisobutyrylfentanyl suggested by Watanabe et al. (2017), which 
summarize the results obtained from in vitro incubations with 10-donor pooled human hepatocytes and authentic 
human urine samples. Enclosed metabolites: major metabolites detected in hydrolysed human urine specimen; 
metabolites in italics only found in either the in vitro or in vivo experiment.  
A limited number of self-reported user experiences have noted that the duration of effects induced by 4-
fluoroisobutyrylfentanyl could be greater than 12 hours (19,20). If correct, then this would indicate a longer 
lasting activity compared to fentanyl and other fentanyl analogues available on the market. As noted in 
the introduction, given the difficulties of collecting such data, these reports should be viewed with caution. 
Inter-individual genetic variability in metabolising enzymes 
For fentanyl, oxidative dealkylation by hepatic CYP3A4 and by CYP3A5 isoenzymes to norfentanyl has 
been demonstrated (Guitton et al., 1997, Jin et al., 2005, Labroo et al., 1997). The variation of the 
expression of the genes coding for these CYP3A isoenzymes among populations might be of clinical 
significance (Meyer and Maurer, 2011) but further studies are needed to address the toxicological 
consequences of such polymorphisms.  
  
                                                     
(19) https://forum.drugs-and-users.org/index.php?topic=3373.0 (last accessed 22.10.2017). 
(20) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) (last accessed 22.10.2017). 
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Interactions with other substances and other interactions 
Specific information about 4-fluoroisobutyrylfentanyl could not be identified although it seems conceivable 
that interactions observed with fentanyl might equally apply (Preston, 2016). For example, should 4-
fluoroisobutyrylfentanyl undergo oxidative dealkylation by hepatic CYP3A4 and by CYP3A5 isoenzymes 
then the use of this substance with inhibitors of these isoenzymes, such as clarithromycin, erythromycin, 
fluconazole, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone, ritonavir, saquinavir, 
suboxone, verapamil) (21) may result in increased plasma concentration of 4-fluoroisobutyrylfentanyl. This 
could increase the risk of poisoning, including potentially fatal respiratory depression.  
The concomitant use of other central nervous system (CNS) depressants, including other opioids, 
sedatives/hypnotics (such as the benzodiazepines and the z-drugs), ethanol, pregabalin, gabapentin, 
tranquillisers, and sedating anti-histamines, may produce additive depressant effects.  
The use of fentanyl with serotoninergic agents, such as selective serotonin re-uptake Inhibitors (SSRIs) 
(the most commonly prescribed antidepressants) or serotonin norepinephrine re-uptake inhibitors (SNRIs) 
or monoamine oxidase inhibitors (MAOIs) has been associated with a serotonin syndrome, a potentially 
life-threatening condition. This association is likely to extend to illicit drugs, which act on the serotonergic 
system. It is not known if this association is also seen with 4-fluoroisobutyrylfentanyl.  
Effects on ability to drive and operate machines 
No studies of the effects of 4-fluoroisobutyrylfentanyl on the ability to drive and operate machines have 
been performed. However, it is well established that opioid analgesics, such as fentanyl, impair the 
mental and physical ability required to drive and operate machines. This effect is likely to extend to 4-
fluoroisobutyrylfentanyl. 
A3. Psychological and behavioural effects 
Information on the psychological and behavioural effects of 4-fluoroisobutyrylfentanyl is limited. It appears 
that the psychoactive profile of 4-fluoroisobutyrylfentanyl might share at least some similarities with other 
opioid analgesics such as fentanyl and heroin. These would include relaxation and euphoria; at higher 
doses, sedation and profound intoxication may occur. 
A limited number of self-reported user experiences have noted that 4-fluoroisobutyrylfentanyl is  
 and is less euphorigenic when compared to other opioids (22,23,24). As noted in the introduction, 
given the difficulties of collecting such data, these reports should be viewed with caution. In addition, it 
should be noted that if 4-fluoroisobutyrylfentanyl was indeed less euphorigenic, this might lead to users 
increasing the dose, which could increase the risk of opioid toxicity and particularly life-threatening 
respiratory depression. 
                                                     
(21) For a more comprehensive list of drug interactions with fentanyl, see, for example, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124&source=ho
meMedSearch&keyword=fentanyl&category=human&isNewQuery=true 
(22) https://forum.drugs-and-users.org/index.php?topic=3373.0 (last accessed 22.10.2017). 
(23) http://www.bluelight.org/vb/threads/774831-Novel-opioid-4-Fluoroisobutyrfentanyl-(4-FiBF-p-FiBF) (last accessed 22.10.2017). 
(24) https://www.reddit.com/r/opiates/comments/3ved25/anybody_try_furanylfentanyl_fuf_or/ (last accessed 22.10.2017). 
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A4. Legitimate uses of the product  
4-Fluoroisobutyrylfentanyl is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests 4-
fluoroisobutyrylfentanyl is used for other legitimate purposes. 
There are no reported uses of 4-fluoroisobutyrylfentanyl as a component in industrial, cosmetic or 
agricultural products. In addition, a search of the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) registered substances database hosted by the European Chemicals Agency (ECHA) 
using the CAS Registry Number returned no results. 
There is no marketing authorisation (existing, on-going or suspended) for 4-fluoroisobutyrylfentanyl 
neither in the European Union nor in the Member States that responded to the request for information 
from the European Medicines Agency, which was undertaken as part of the Joint Report process 
(EMCDDA, 2017a) 
There is no information to suggest that 4-fluoroisobutyrylfentanyl is currently used in the manufacture of a 
medicinal product in the European Union. However, in the absence of a database on the synthetic routes 
of all medicinal products it is not possible to confirm whether or not 4-fluoroisobutyrylfentanyl is currently 
used in the manufacture of a medicinal product.  
Section B. Dependence and abuse potential 
B1. Animal data  
No studies were identified that have investigated the dependence and/or abuse potential of 4-
fluoroisobutyrylfentanyl in animal models. 
The related des-fluoro analogue, isobutyrylfentanyl (NIH 10487) (Aceto et al., 1988) was studied in 
rhesus monkeys that received 3.0 mg/kg s.c. of morphine sulfate every 6 h for at least 90 days. In the 
single dose substitution test in rhesus monkeys, NIH 10487 (evaluated at 0.025 mg/kg and 0.1 mg/kg) 
substituted completely for morphine. Potency estimate is 30 times [that of] morphine. Rapid onset and 
2.5h duration of action were observed. Sagging, ataxia, slowing and scratching were noted at the highest 
dose during the first hour  
B2. Human data  
No studies were identified that have investigated the dependence and/or abuse potential of 4-
fluoroisobutyrylfentanyl in humans.  
Whereas no specific data exist for 4-fluoroisobutyrylfentanyl, it is well established that opioid analgesics 
such as fentanyl have an abuse liability and can induce tolerance and dependence. Research is required 
in order to examine these effects with 4-fluoroisobutyrylfentanyl. 
Section C. Prevalence of use 
Information from seizures, collected and biological samples 
4-Fluoroisobutyrylfentanyl was formally notified on 26 August 2016 by the EMCDDA on behalf of the 
Slovenia, in accordance with Article 4 of the Council Decision. The Reporting Form details a collected 
sample of 5 grams of white powder that was test-purchased as part of the EU co-funded RESPONSE 
project, and analysed on 25 May 2016 in Ljubljana. 4-Fluoroisobutyrylfentanyl was analytically confirmed 
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by GC-MS, HPLC-TOF, FTIR-ATR, GC-MS-IR, ion chromatography and NMR by the Slovenian National 
Forensic Laboratory and the Faculty of Chemistry and Chemical technology of the University of Ljubljana 
(EMCDDA, 2017a). 
Since then, a total of 5 Member States (Belgium, Germany, Slovenia, Sweden and the United Kingdom) 
have reported detections (25) of 4-fluoroisobutyrylfentanyl (EMCDDA, 2017a). 
It is important to note that detections of 4-fluoroisobutyrylfentanyl may be under-reported since the 
substance is not routinely screened for. Three Member States (Austria, Slovenia and Sweden) and 
Norway reported that 4-fluoroisobutyrylfentanyl is part of routine screening in some (but not all) 
laboratories. 
Information from seizures 
Information reported to the EMCDDA and Europol indicates that 24 seizures of 4-fluoroisobutyrylfentanyl 
have been reported by 4 Member States: Sweden (20 seizures), Belgium (1), Germany (1), and the 
United Kingdom (2). The majority of the seizures took place in 2016, while the most recent events took 
place in 2017. 
Additionally, Finland reported a seizure of 0.05 g of a powder which was reported as -, 3F- or 4F-BF; 
2F-, 3F- or 4F-  as the exact isomer was not be determined. This case is not discussed further in this 
report. 
No information regarding the purity of the samples was provided. 
Powders 
A total of 9 seizures of powders were reported by: Belgium, Germany, Sweden, and the United Kingdom, 
amounting to a total of 378.6 g. 
The powder seizure reported by Germany also contained furanylfentanyl. In one case reported by the 
United Kingdom, the powder also contained furanylfentanyl and an unspecified isomer of fluorofentanyl . 
In the other seizure reported by the United Kingdom, a number of different items were seized, and 
different substances identified, including heroin, cocaine, steroids and synthetic cannabinoids (5F-MDMB-
PINACA and MMB-FUBINACA). Nine of the items were found to contain 4-fluoroisobutyrylfentanyl, as 
follows:  
 0.436 grams of crystalline powder which appeared to be pure 4-fluoroisobutyrylfentanyl (no other 
compounds detected in the crystals); 
 0.425 grams of brown powder, found to contain mainly 4-fluoroisobutyrylfentanyl mixed with 
smaller amounts of paracetamol and caffeine;  
                                                     
(25)  is an all-encompassing term and may include seizures and/or collected and/or biological samples that are 
analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, border 
guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test purchases) for 
monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or specimens 
(tissues, hair, etc.) 
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 7 items, consisting of heroin containing paracetamol, caffeine and 4-fluoroisobutyrylfentanyl. 
These were of various strengths of heroin and 4-fluoroisobutyrylfentanyl which were not 
determined. The total weight of these powders was 105.8 g. 
Other physical forms 
Sweden reported seizures of 4-fluoroisobutyrylfentanyl in tablets and liquids, as follows: 
 12 seizures of tablets, amounting to a total of 6727 tablets; 
 3 seizures of liquids, amounting to a total of 208 millilitres. 
Information from collected samples 
Slovenia reported a sample of 5 g of 4-fluoroisobutyrylfentanyl base in powder form which was purchased 
from an Internet vendor. The sample was apparently shipped from China and was received in May 2016. 
No other substances were detected in the sample 
Information from biological samples 
Serious adverse events (deaths and acute intoxications) with confirmed exposure to 4-
fluoroisobutyrylfentanyl from biological samples are discussed in Section D. 
Availability, supply, price 
Information on production 
No information was received in relation to the production of 4-fluoroisobutyrylfentanyl. 
Information on trafficking 
No information was reported to the EMCDDA in relation to the trafficking of 4-fluoroisobutyrylfentanyl. 
Information on the source of 4-fluoroisobutyrylfentanyl is limited to one report regarding collected sample 
of the substance. Here, the substance was ordered from an online vendor apparently based in China (see 
above). In addition, Belgium reported a seizure of 4-fluoroisobutyrylfentanyl to the EMCCDA where the 
final destination was Germany. 
Availability from Internet vendors 
A structured search of online vendors on the surface web by the EMCDDA (26) found that the substance 
is offered for sale online in small and wholesale amounts, typically as a   and as 
powders, liquids, and blotters. 
On the websites identified, 4-fluoroisobutyrylfentanyl was available in powder, liquid and blotter form. For 
powders, amounts on sale ranged from 0.5 grams to 10 kg, for liquids 5 to 50 mL and for blotters 1 to 500 
                                                     
(26) The search for online vendors of 4-fluoroisobutyrylfentanyl on the surface web was performed on 06/06/2017 using previously 
established methodology (EMCDDA, 2017c). The search identified 31 vendors that appeared to be based in, and/or claim to have 
presence in China (n=18), India (n=3), USA (n=2), Hong Kong (n=2), Hungary (n=1), Sweden (n=1), Turkey (n=1) and European 
Union (not specified) (n=1); the remaining 2 websites did not list a location. Nineteen websites listed quantities and prices for4-
fluoroisobutyrylfentanyl. The remaining websites only provided prices on request. 
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units. Prices varied according to the amounts on sale. Powders ranged from EUR 0.7 per gram to EUR 
238 per gram. Liquids and blotters were only sold in one internet retailer. The price of the liquids varied 
from EUR 1 to EUR 5 per mL; for blotters a price of EUR 1 per unit was indicated. 
The availability of 4-fluoroisobutyrylfentanyl on the darknet is not currently known. 
Prevalence of use  
No studies were identified that have investigated the prevalence of use of 4-fluoroisobutyrylfentanyl in the 
general population. Given its pharmacology and that it is sold openly as a  replacement to illicit 
opioids, it would be expected that users looking for substitutes for opioids, which would include individuals 
who use illicit opioids, such as heroin and/or prescription opioids, may seek out 4-fluoroisobutyrylfentanyl 
and other fentanils. It also appears that there is interest in this substance by some psychonauts. Overall, 
the available information does not suggest widespread use of the substance. 
Of additional note is that, in the past few years, fentanils have been sold in Europe as ready-to-use nasal 
sprays. In some cases they have also been sold as e-liquids for vaping. In general, these novel products 
could make it easier to use such substances (with similar effects to injecting) and make them more 
socially acceptable, potentially expanding their use in new user groups. These are new developments 
that will require careful monitoring. 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
Data on the acute toxicity, abuse liability, and dependence producing potential of 4-
fluoroisobutyrylfentanyl could not be identified.  
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of 4-
fluoroisobutyrylfentanyl and/or its metabolites in humans. Although the pharmacology and toxicology of 4-
fluoroisobutyrylfentanyl remains largely unstudied, the available data suggests that the nature of its 
effects share some similarities with opioid analgesics such as morphine and fentanyl.  The acute effects 
of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, hypothermia, 
miosis, and respiratory depression or arrest. They also have an abuse liability and dependence potential 
(Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute health risk associated with 4-
fluoroisobutyrylfentanyl use is probably respiratory depression, which can lead to apnoea, respiratory 
arrest and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999). This risk may be 
greater due to: the difficulty in diluting the substance; a lack of experience with its effects and dosing; the 
use of other central nervous system depressants at the same time (such as other opioids, 
benzodiazepines, gabapentanoids, and alcohol); a lack of tolerance to opioids; and, using the substance 
alone (such as at home) which would make it more difficult for users to call for help in the case of 
poisoning. 
The antidote naloxone should reverse acute poisoning caused by 4-fluoroisobutyrylfentanyl (Kim and 
Nelson, 2015). 
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Recent clinical and community experience in treating poisonings caused by fentanils suggests that larger 
than normal doses and repeated doses of naloxone may be required to manage the poisoning in some 
cases; longer periods of observation may also be required (Klar et al., 2016; Moss et al., 2017; Somerville 
et al., 2017; Sutter et al., 2017). 
There is a lack of information on the clinical features of poisoning caused by 4-fluoroisobutyrylfentanyl. 
Nonetheless, the available data suggests that the nature of the effects of 4-fluoroisobutyrylfentanyl share 
some similarities with opioid analgesics such as morphine and fentanyl. As a result, features of poisoning 
are likely to include reduced level of consciousness or unconsciousness, respiratory depression and 
arrest, and miosis (27). 
Acute intoxications reported by the Member States 
No acute intoxications with confirmed exposure to 4-fluoroisobutyrylfentanyl were reported (27,28). 
Acute intoxications identified from other sources 
No cases of acute intoxications were identified from other sources (27). 
Deaths reported by the Member States 
A total of 20 deaths were reported by 2 Member States: Sweden (16) and the United Kingdom (4). 
Exposure to 4-fluoroisobutyrylfentanyl was analytically confirmed in post-mortem samples in all cases 
from Sweden; no reference standard was available to distinguish between 4-fluoroisobutyrylfentanyl and 
4-fluorobutyrylfentanyl in cases from the United Kingdom.  
The deaths occurred between July 2016 and March 2017, with 17 occurring in 2016 and 3 in 2017. 
Of the 18 deaths where demographic data were available, 16 were male (80%) and 2 were female (20%). 
The mean age of the males was 35 years (median 34) and ranged from 20 to 52 years; the age of the 
females was 24 and 36 years. 
Circumstances and cause of death 
In the majority of cases there was a lack of information regarding any symptoms experienced by the 
deceased prior to death, but, where described in a few cases, the deceased had become unconscious 
                                                     
(27) Information on the clinical features of intoxication caused by 4-fluoroisobutyrylfentanyl is limited to a single report involving a 
death published by Helander et al., (2017). In this case, a male user had apparently injected intravenously 250 mg of 4-
fluoroisobutyrylfentanyl and was   The main features reported were unconsciousness, apnoea, and asystole. 
The patient  discovered lifeless with a syringe reportedly containing -  next to him. Cardiopulmonary resuscitation (CPR) 
was initiated by relatives. On ambulance arrival, the first recorded rhythm was asystole and CPR was maintained with an automated 
device. He was given 0.4mg of naloxone and repeated 1mg doses of adrenaline intravenously. Palpable pulses appeared only 
transiently and CPR was maintained during transport to hospital. Return of spontaneous circulation occurred after 90 min of CPR. 
The patient was unconscious (RLS 8), had dilated pupils unresponsive to light, and was normothermic. He was intubated, put on 
ventilator, and mildly therapeutically cooled to the target 36 (C (96.8 (F) body temperature, according to hospital guidelines. An early 
computed tomography (CT) showed brain edema. His neurological condition did not improve during the following 24 h and he was 
declared dead 43 h after arriving to hospital  (Helander et al., 2017). This case is included in the deaths reported by the Member 
States. 
(28) Sweden reported 2 acute intoxications with suspected exposure to 4-fluoroisobutyrylfentanyl. These cases are not discussed 
further in this report. 
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and in one case the deceased was found convulsing. Where information was known, in the majority of 
instances the individuals were found dead, predominantly in a home environment (either their own or a 
 Consequently, it was not possible to identify or evaluate ante-mortem symptoms (especially in 
relation to acute intoxication) in these cases. 
The cause of death was reported in 16 out of 20 cases. In at least 13 deaths, intoxication with 4-
fluoroisobutyrylfentanyl was reported either as the primary cause of death or as likely to have contributed 
to death (even in presence of other substances); other substances were detected in 19 cases (with 
creatinine detected in the remaining case). 
4-Fluoroisobutyrylfentanyl was quantified in 16 cases. Post-mortem femoral blood concentrations ranged 
from 0.76 to 370 ng/g blood (median 41 ng/g blood). In 2 cases, although the concentration was 
measured (44 and 85 ng/mL), it was not possible to determine if it related to 4-fluoroisobutyrylfentanyl or 
4-fluorobutyrylfentanyl. Due to the toxicity of potent opioids and variability in user tolerance, determination 
of a fata  concentration based on a post-mortem blood concentration is not reliable. In the majority of 
circumstances involving fentanils, the mere presence of the drug is of significance whether concentration 
has been determined or not, especially in situations of poly-drug use. 
A range of other substances were detected in the deaths, including: cannabinoids, benzodiazepines, 
amphetamine, zopiclone, zolpidem, gabapentinoids (pregabalin and gabapentin), antidepressants, 
antipsychotics, antihistamines, a synthetic cathinone (alpha-PHP), ketamine and ethanol. Other 
opiates/opioids were detected in 9 of the deaths; codeine, buprenorphine, tramadol, methadone, 
oxycodone, fentanyl, despropionylfentanyl, tetrahydrofuranylfentanyl, and acryloylfentanyl. 
Overall, whilst other substances may have contributed some toxicity, a synergistic effect with 4-
fluoroisobutyrylfentanyl would have been likely with other central nervous system depressants such as 
ethanol, benzodiazepines, opioids, etc. Nevertheless, the potent opioid nature of 4-
fluoroisobutyrylfentanyl means that the primary toxic contribution could be attributed to 4-
fluoroisobutyrylfentanyl and death may not have occurred if 4-fluoroisobutyrylfentanyl had not been used. 
An assessment of the Toxicological Significance Score (TSS) (Elliott, Sedefov, & Evans-Brown, 2017) 
incorporating the above considerations shows that 4-fluoroisobutyrylfentanyl had a TSS value of 3 (high) 
in 15 out of 16 of the deaths (where it was cited as the cause of death or is likely to have contributed to 
death). In the remaining death, an alternative cause of death (drowning) was cited (TSS value of 1, low). 
The 4 cases where 4-fluoroisobutyrylfentanyl could not be unequivocally confirmed were not part of the 
assessment. 
Deaths identified from other sources 
Since August 2016, more than 60 deaths associated with 4-fluoroisobutyrylfentanyl have been reported in 
the United States (US DEA, 2017b). 
D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that have investigated the chronic health effects of 4-fluoroisobutyrylfentanyl in 
animals. 
D2.2. Human data 
No studies were identified that have investigated the chronic health effects of 4-fluoroisobutyrylfentanyl in 
humans. 
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D3. Factors affecting public health risks 
D3.1. Availability and quantity of the new psychoactive substance on the market 
4-Fluoroisobutyrylfentanyl is being sold on the surface web as a drug in its own right. It is sold in both 
retail and wholesale quantities. It has been sold as a   in powder form, liquids, and 
blotters. 
4-Fluoroisobutyrylfentanyl is also used to make tablets, as evidenced by the 12 seizures by Swedish 
Police of 6727 tablets. No further details are available on these cases. 
Information from a seizure case in the United Kingdom suggests that 4-fluoroisobutyrylfentanyl has been 
sold on the illicit opioid market in mixtures with heroin. 
D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
Due to its relatively recent availability on the drug market, the availability of information, degree of 
knowledge and perceptions amongst users concerning 4-fluoroisobutyrylfentanyl and its effects are 
limited. 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviours of users of 4-
fluoroisobutyrylfentanyl. Section C (above) and Section E6 (below) provides additional information on the 
likely user groups of 4-fluoroisobutyrylfentanyl. 
D3.4. Nature and extent of health consequences 
Acute health risks 
Although the pharmacology and toxicology of 4-fluoroisobutyrylfentanyl remains largely unstudied, the 
available data suggests that the nature of its effects share some similarities with opioid analgesics such 
as morphine and fentanyl.  
The acute effects of these types of opioids include: euphoria, relaxation, analgesia, sedation, bradycardia, 
hypothermia, and respiratory depression. They also have an abuse liability and dependence potential 
(Cox, 2011; Dahan et al., 2001; Pattinson, 2008; Romberg et al., 2003). 
Similar to other opioid analgesics, the most serious acute risk arising from the use of 4-
fluoroisobutyrylfentanyl is probably from respiratory depression, which can lead to apnoea, respiratory 
arrest, and death (Cox, 2011; Dahan et al., 2001; Pattinson, 2008; White & Irvine, 1999).  
In general, this risk may be exacerbated by:  
 the difficulty in diluting/using fentanils (as they are typically highly potent), which can lead to a 
toxic dose being accidentally used (de Boer et al., 2003; Sutter et al., 2017); 
 the apparent rapid onset of severe poisoning following use (Somerville et al., 2017); 
 central nervous system (such as injecting, insufflation, and inhalation) (Macleod et al., 2012);  
 availability of easy to use dosage forms (such as nasal sprays and e-liquids); 
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 use of other central nervous system depressants (such as other opioids, benzodiazepines, and 
alcohol) (e.g. van der Schrier et al., 2017) ;  
 lack of tolerance to opioids in opioid-naïve persons (such as new or former users); 
 use in environments where it may be difficult to summon help in the event of poisoning (e.g. 
alone in a home environment) (Somerville et al., 2017); 
 limited availability of the antidote naloxone in community settings (EMCDDA, 2015; EMCDDA, 
2016b; Somerville et al., 2017). 
In addition, and, often unknown to users, the fentanils are sold as heroin or mixed with heroin. They are 
also used to make counterfeits of highly sought-after analgesics and benzodiazepines. They have also 
been sold in or as drugs such as cocaine (Klar et al., 2016; SFDPH, 2015; Sutter et al., 2017; Tomassoni 
et al., 2017). Due to this, users may not be aware that they are using a fentanil; in some cases these 
individuals will have no tolerance to opioids nor access to community naloxone programmes. Overall, 
these factors may increase the risk of life-threatening poisoning. 
Given the above risks, poisonings by fentanils may manifest as outbreaks which have the potential to 
overwhelm emergency responders and other local healthcare systems (Klar et al., 2016; SFDPH, 2015; 
Sutter et al., 2017; Tomassoni et al., 2017). 
Accidental exposure to the fentanils may also pose a risk to non-users, including family and friends, law 
enforcement and emergency responders. Such risks may need to be assessed so that, where required, 
appropriate procedures, training and environmental and personal protective measures can be provided 
for handling materials suspected to contain these substances (US CDC, 2016; Moss et al., 2017; US 
DEA, 2017a). Any required responses should continue to ensure the delivery of prompt and appropriate 
care to patients with suspected overdose (Cole & Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
Managing poisoning 
The antidote naloxone should reverse acute poisoning caused by 4-fluoroisobutyrylfentanyl (Kim and 
Nelson, 2015; Ujváry et al., 2017). Recent clinical and community experience in treating poisonings 
caused by fentanils suggests that larger than normal doses and repeated doses of naloxone may be 
required to manage the poisoning in some cases; longer periods of observation may also be required 
(Klar et al., 2016; Moss et al., 2017; Somerville et al., 2017; Sutter et al., 2017). This may reflect, among 
other factors, the high potency of the fentanils, their half-lives, the dose an individual is exposed to, and, 
the relatively short half-life of naloxone. 
Chronic health risks 
While there is limited data, the chronic health risks of carfentanil might share some similarities to opioids 
such as heroin and other fentanils. This may include dependence. 
D3.5. Long-term consequences of use 
While there is limited data, the chronic health risks of 4-fluoroisobutyrylfentanyl might share some 
similarities to opioids such as heroin and other fentanils. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks 
There is limited data on the conditions under which 4-fluoroisobutyrylfentanyl is obtained and used. 4-
Fluoroisobutyrylfentanyl is offered for sale on the surface web as a powder, liquids, and blotters. 
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It has also been seized as tablets. Information from a seizure case in the United Kingdom suggests that 
4-fluoroisobutyrylfentanyl has been sold on the illicit opioid market in mixtures with heroin. 
Section E. Social Risks 
While there have been no studies on the social risks of 4-fluoroisobutyrylfentanyl, it is likely that some of 
the risks are similar to those associated with illicit opioids, including fentanyl and heroin. 
E1. Individual social risks 
There is no information on the individual social risks that may be associated with the use of 4-
fluoroisobutyrylfentanyl. Given that 4-fluoroisobutyrylfentanyl appears to act as an opioid analgesic, any 
such risks may have some similarities with those associated with illicit opioids. These may negatively 
impact on education or career, family or other personal and social relationships and may result in 
marginalisation. 
E2. Possible effects on direct social environment  
There is no information on the possible effects of 4-fluoroisobutyrylfentanyl on the direct social 
environment. Given that 4-fluoroisobutyrylfentanyl appears to act as an opioid analgesic, any such effects 
may have some similarities with those associated with the use of illicit opioids. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of 4-fluoroisobutyrylfentanyl on society as a whole.  
As discussed above, accidental exposure to the fentanils may pose a risk of poisoning to those who may 
come into contact with the substances. This includes the family and friends of users, law enforcement, 
emergency personnel, medical and forensic laboratory personnel as well as custodial settings and postal 
services. Where required, these risks should be assessed and appropriate procedures, training, and 
protective measures should be implemented. This may include training in managing poisoning, including 
in resuscitation and adequate provision of naloxone to reverse poisoning. Any required responses should 
continue to ensure the delivery of prompt and appropriate care to patients with suspected overdose (Cole 
& Nelson, 2017; Lynch, Suyama, & Guyette, 2017). 
E4. Economic costs 
There are no data on the health and social costs related to 4-fluoroisobutyrylfentanyl. 
E5. Possible effects related to the cultural context, for example marginalization 
There are no data on the possible effects of 4-fluoroisobutyrylfentanyl related to the cultural context. 
E6. Possible appeal of the new psychoactive substance to specific population groups within the 
general population 
While no specific examples are available on the possible appeal of 4-fluoroisobutyrylfentanyl to specific 
user groups (aside from psychonauts), it is reasonable to assume 4-fluoroisobutyrylfentanyl may be 
sought by those looking for  substitutes for illicit opioids, such as heroin and/or prescription opioids.  
As discussed above, the open sale of fentanils in novel dosage forms such as ready-to-use nasal 
sprays and e-liquids for vaping poses additional concerns. These novel forms have the potential to 
make the use of fentanils easier (with similar effects to injecting) and more socially acceptable. 
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Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking and 
distribution for financial gain 
There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of 4-fluoroisobutyrylfentanyl. 
Slovenia reported a collected sample of 4-fluoroisobutyrylfentanyl to both Europol and the EMCDDA 
where the country of origin was indicated as China. 
Belgium reported a seizure of 4-fluoroisobutyrylfentanyl to the EMCCDA where the final destination was 
Germany. 
The seizure of an illicit laboratory producing fentanils in Europe in 2013 (EMCDDA, 2017e) suggests that 
the capability to manufacture fentanils may exist within the European Union. 
F2. Impact on the production, trafficking and distribution of other substances, including existing 
psychoactive substances as well as new psychoactive substances 
No information was reported nor identified concerning the impact of 4-fluoroisobutyrylfentanyl on the 
production, trafficking and distribution of other substances, including existing psychoactive substances as 
well as new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of 4-fluoroisobutyrylfentanyl. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or local 
communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability of 4-
fluoroisobutyrylfentanyl. 
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or impact 
of organised crime on other socioeconomic factors in society related to the availability of 4-
fluoroisobutyrylfentanyl. 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)  
No information was reported nor identified concerning the economic costs and consequences related to 
the availability of 4-fluoroisobutyrylfentanyl. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of 4-fluoroisobutyrylfentanyl. 
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F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of 4-fluoroisobutyrylfentanyl.  
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